



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ping Gao, et al.
Serial No: 10/047,902
Filed: January 14, 2002
Title: Chemotherapeutic Microemulsion Compositions of Paclitaxel with Improved Oral Bioavailability
Confirmation No: 5445
Group Art Unit: 1653
Examiner: Suzanne M. Mayer
Attorney Ref: 6239/1/US
Pfizer Ref: 31437/USA
HDP Ref: 6794-000148/US

August 24, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 C.F.R. §1.97 and §1.98, Applicants have enclosed Form 1449 and all references cited on that form. In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form 1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a

EV 639015271 US

complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

As to reference CH 688 504 A5, Applicants have enclosed an English translation of page 9, line 49 to page 10, line 59 and page 18, line 44 to page 19, line 28. Applicants make no representation as to the accuracy of the translation.

Applicants request early and favorable consideration of this application.

This supplemental information disclosure statement is filed together with a request for continued examination. Thus, Applicants believe that they do not owe any fee for filing this supplemental information disclosure statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge such fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



Lydia N. Nenow, PTO Reg. No. 52,530
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **August 24, 2005** with sufficient postage as first class mail (including Express Mail per MPEP §512), and addressed to **Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



Lydia N. Nenow



PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 1 of 1	ATTORNEY DOCKET No.	SERIAL No.
	6239/1/US (31437/USA; 6794-000148/US)	10/047,902
	APPLICANT	
	Ping Gao, et al.	
	FILING DATE	GROUP
	January 14, 2002	1653

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
1.		CH 688 504 A5	10/31/1997	Switzerland	A61K 031/015	partial

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
2.		Eiseman et al, <i>Plasma Pharmacokinetics and Tissue Distribution of Paclitaxel in CD₂F₁ Mice</i> , CANCER CHEMOTHER PHARMACO. 34:465-471 (1994)
3.		Slater et al, <i>Comparison of Cyclosporin A, Verapamil, PSC-833 and Cremophor EL As Enhancing Agents of VP-16 in Murine Lymphoid Leukemias</i> , LEUKEMIA RESEARCH 19(8):543-548 (1995)
4.		Sharma et al, <i>Novel Taxol® Formulation: Polyvinylpyrrolidone Nanoparticle-Encapsulated Taxol® for Drug Delivery in Cancer Therapy</i> , ONCOLOGY RESEARCH 9(7/8):281-286 (1996)
5.		International Search Report for International Patent Application No. PCT/US02/00497

EV 639015271 US

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.